Enveda Series E Doubles Valuation to $2B; Kinnevik Stake Gains

Enveda raised $311M in Series E led by Catalio Capital, doubling its valuation to $2B from a year ago. Kinnevik, a major investor, sees its holding value increase, though the exact stake and realized gains remain undisclosed. This marks a notable private-market up-round in biotech, signaling continued investor appetite for drug discovery platforms.